Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > REGULATORY
REGULATORY
- Chuikyo OKs Plan for September Drug Price Survey, Smaller Coverage amid COVID-19
July 22, 2020
- Reinstate “Active Recommendation” for HPV Vaccines: LDP Lawmakers’ League
July 22, 2020
- Label Revisions Ordered for Iopamiron, 5 Other Contrast Media
July 22, 2020
- September Drug Price Survey Likely as MHLW to Keep Its Proposal Unchanged
July 21, 2020
- Kadcyla, Keytruda, Imfinzi in Line for Label Expansion in August
July 20, 2020
- 2020 Policy Blueprint Restresses Efforts on COVID-19 Meds/Vaccines; Drug Price Survey Up for Discussion on July 22
July 20, 2020
- Japan Might Tap Coronavirus Emergency Reserve for Vaccines
July 17, 2020
- Japan Govt Adopts 2020 Honebuto Policy, Drug Price Survey to Be Conducted This Autumn
July 17, 2020
- Otsuka Pharmaceutical Factory’s Infusion Solution in Line for September Approval
July 16, 2020
- Japan Govt to Push Ahead with Off-Year Survey, Considering COVID-19 Impact to Decide on Re-Pricing
July 16, 2020
- Japan Govt Maps Out Action Strategy for Regulatory Harmonization in Asia
July 15, 2020
- Health Minister Asks Makers to Boost Syringe, Needle Production for Coronavirus Vaccines
July 15, 2020
- Coronavirus-Neutralizing Antibodies Detected in Japan for 1st Time
July 15, 2020
- Japan Govt to Tweak Honebuto Text for Off-Year Re-Pricing, but Still Holds to Original Plan
July 15, 2020
- LDP Lawmakers Irked as Govt Stands Fast on Off-Year Re-Pricing/Survey Plan; Honebuto Text Tweak Unclear
July 10, 2020
- MHLW’s OTC Panel Begins Discussions toward Interim Report; to Seek Solutions for Problems in Switch-OTC Approval
July 10, 2020
- Original Plan Remains Unchanged for Off-Year Drug Re-Pricing, Survey: Minister
July 9, 2020
- AnGes’ COVID-19 Vaccine Given Some Safety Confirmation Before Clinical Trial: MHLW Official
July 9, 2020
- LDP Lawmakers’ League to Launch Group to Protect People against HPV
July 8, 2020
- MHLW Set to Approve Label Expansions for Kadcyla, Keytruda, Imfinzi and More
July 7, 2020
ページ
More than a year after Dupixent (dupilumab) became the first antibody therapy approved for COPD in Japan, drug makers are…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…